Arvinas Competitors and Similar CompaniesClear all

Arvinas's competitors and similar companies include Lyell, Foghorn Therapeutics, NextCure and Stelexis Therapeutics.
Arvinas
Arvinas
Arvinas is a biopharmaceutical company focused on developing protein degradation therapeutics for cancers and other diseases.
Lyell
Lyell
Lyell Immunopharma is a T-cell reprogramming company to cure patients with solid tumors.
Foghorn Therapeutics
Foghorn Therapeutics
Foghorn Therapeutics is a developer of gene therapies for hematologic cancers and solid tumors.
NextCure
NextCure
NextCure is a biopharmaceutical company focused on discovering and developing next-generation immuno-oncology-based drugs.
Stelexis Therapeutics
Stelexis Therapeutics
Stelexis Therapeutics is a cancer therapeutics company.
Founding Date
Founding Date
N/A
Founding Date
2018
Founding Date
2016
Founding Date
2015
Founding Date
2017
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Private
Tags
Locations
Locations
New Haven, US HQ
Locations
South San Francisco, US HQ
Bothell, US
Seattle, US
Locations
Cambridge, US HQ
Cambridge, US
Locations
Beltsville, US HQ
Locations
New York, US HQ
Employees
Employees
13329% increase
Employees
188
Employees
16135% increase
Employees
N/A
Employees
3
Valuation ($)
Valuation ($)
2.2 b
Valuation ($)
698.5 m
Valuation ($)
225.3 m
Valuation ($)
46.2 m
Valuation ($)
N/A
Twitter followers
Twitter followers
3.1 k
Twitter followers
N/A
Twitter followers
1.1 k
Twitter followers
N/A
Twitter followers
N/A
Number of tweets (last 30 days)
Number of tweets (last 30 days)
13
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
9
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
N/A
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
2
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
2.3
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
84.62%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
88.89%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
N/A

Financial

Revenue (est.)
Revenue (est.)
$78.5m (FY, 2023)
Revenue (est.)
$130k (FY, 2023)
Revenue (est.)
$34.2m (FY, 2023)
Revenue (est.)
N/A
Revenue (est.)
N/A
Net income
Net income
($367.3m) (FY, 2023)
Net income
($234.6m) (FY, 2023)
Net income
($98.4m) (FY, 2023)
Net income
($62.7m) (FY, 2023)
Net income
N/A

Funding

Total funding raised
Total funding raised
$ 111.6m
Total funding raised
N/A
Total funding raised
$ 50m
Total funding raised
$ 160m
Total funding raised
$ 43m
For sources of this data, please see the company profile

View Company Profiles

Lyell
HQ
South San Francisco, US
Employees
188

Lyell Immunopharma is a T-cell reprogramming company to cure patients with solid tumors.

View company
Foghorn Therapeutics
HQ
Cambridge, US
Employees
161↑ 35% increase

Foghorn Therapeutics is a developer of gene therapies for hematologic cancers and solid tumors.

View company
NextCure
HQ
Beltsville, US

NextCure is a biopharmaceutical company focused on discovering and developing next-generation immuno-oncology-based drugs.

View company
Stelexis Therapeutics
HQ
New York, US
Employees
3

Stelexis Therapeutics is a cancer therapeutics company.

View company